News articles about Sangamo Therapeutics (NASDAQ:SGMO) have trended somewhat positive on Monday, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Sangamo Therapeutics earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 44.8436295797827 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) – Is The Stock A Good Investment? – Alpha Beta Stock (alphabetastock.com)
- Who Are The Top Investors In Sangamo Therapeutics Inc (SGMO)? (finance.yahoo.com)
- Sangamo Therapeutics, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (prnewswire.com)
- Why Investors remained buoyant on: Sangamo Therapeutics, Inc., (NASDAQ: SGMO), Whiting Petroleum Corporation … – Stocks In The News (press release) (tradingnewsnow.com)
- Sangamo Therapeutics, Inc. (SGMO) Earns Overweight Rating from Analysts at Barclays PLC (americanbankingnews.com)
A number of equities research analysts have recently issued reports on SGMO shares. Wells Fargo & Company restated an “outperform” rating and issued a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a research report on Tuesday, September 5th. Jefferies Group LLC restated a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Piper Jaffray Companies upgraded Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target for the company in a research report on Wednesday, November 15th. Zacks Investment Research upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Wednesday, November 15th. Finally, Wedbush reiterated a “hold” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $17.83.
Sangamo Therapeutics (NASDAQ:SGMO) opened at $14.75 on Monday. Sangamo Therapeutics has a twelve month low of $2.65 and a twelve month high of $17.06. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.64 and a quick ratio of 5.64.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm had revenue of $11.81 million for the quarter, compared to analysts’ expectations of $10.37 million. During the same period in the prior year, the firm posted ($0.27) earnings per share. The firm’s quarterly revenue was up 333.0% on a year-over-year basis. research analysts anticipate that Sangamo Therapeutics will post -0.79 EPS for the current year.
In related news, VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $15.00, for a total value of $225,000.00. Following the transaction, the vice president now directly owns 15,833 shares in the company, valued at $237,495. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Saira Ramasastry sold 5,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $14.67, for a total value of $73,350.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $73,350. The disclosure for this sale can be found here. Insiders sold 66,000 shares of company stock worth $972,570 over the last quarter. 5.50% of the stock is currently owned by insiders.
WARNING: “Sangamo Therapeutics (SGMO) Earning Somewhat Favorable Press Coverage, Analysis Finds” was posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://transcriptdaily.com/2017/11/27/sangamo-therapeutics-sgmo-earning-somewhat-favorable-press-coverage-analysis-finds.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.